GH Research (NASDAQ:GHRS) Rating Reiterated by HC Wainwright

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $40.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 233.61% from the stock’s previous close.

A number of other research analysts also recently issued reports on GHRS. JMP Securities reduced their price target on GH Research from $50.00 to $39.00 and set a “market outperform” rating on the stock in a report on Friday, March 1st. Canaccord Genuity Group upped their target price on GH Research from $30.00 to $31.00 and gave the company a “buy” rating in a report on Monday.

GH Research Stock Performance

Shares of GHRS stock opened at $11.99 on Tuesday. The company has a market capitalization of $623.84 million, a P/E ratio of -19.98 and a beta of 0.80. GH Research has a fifty-two week low of $5.05 and a fifty-two week high of $14.64. The stock has a 50 day moving average price of $10.51 and a two-hundred day moving average price of $8.07.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). As a group, equities analysts predict that GH Research will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in GHRS. AdvisorShares Investments LLC boosted its position in shares of GH Research by 4.3% during the fourth quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after purchasing an additional 1,977 shares in the last quarter. PEAK6 Investments LLC boosted its holdings in shares of GH Research by 72.9% during the 3rd quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock valued at $405,000 after buying an additional 16,991 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of GH Research by 14.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock worth $617,000 after buying an additional 13,579 shares during the period. Barclays PLC increased its stake in shares of GH Research by 98.2% in the 3rd quarter. Barclays PLC now owns 63,590 shares of the company’s stock worth $640,000 after acquiring an additional 31,500 shares in the last quarter. Finally, Lynx1 Capital Management LP lifted its position in GH Research by 13.8% during the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock valued at $11,087,000 after acquiring an additional 133,804 shares during the period. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).